Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CHL028
MIFTS: 58

Childhood Type Dermatomyositis

Categories: Blood diseases, Bone diseases, Muscle diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Childhood Type Dermatomyositis

About this section

MalaCards integrated aliases for Childhood Type Dermatomyositis:

Name: Childhood Type Dermatomyositis 12 15
Juvenile Dermatomyositis 12 74 52 58 17 71 32
Juvenile Dm 52 58
Dermatomyositis, Childhood Type 71
Childhood Dermatomyositis 12

Characteristics:

Orphanet epidemiological data:

58
juvenile dermatomyositis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Worldwide); Age of onset: Adolescent,Childhood,Infancy; Age of death: normal life expectancy;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Neuronal diseases Nephrological diseases Respiratory diseases Bone diseases Skin diseases Muscle diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare neurological diseases
Rare renal diseases
Rare respiratory diseases
Rare systemic and rhumatological diseases
Rare skin diseases


Sources

Summaries for Childhood Type Dermatomyositis

About this section
NIH Rare Diseases : 52 Juvenile dermatomyositis has some similarities to adult dermatomyositis and polymyositis . It typically affects children ages 2 to 15 years, with symptoms that include weakness of the muscles close to the trunk of the body, inflammation, edema , muscle pain, fatigue, skin rashes, abdominal pain, fever, and contractures . Children with juvenile dermatomyositis may have difficulty swallowing and breathing, and the heart may also be affected. About 20 to 30 percent of children with juvenile dermatomyositis develop calcium deposits in the soft tissue . Affected children may not show higher than normal levels of the muscle enzyme creatine kinase in their blood but have higher than normal levels of other muscle enzymes. Treatment is aimed at addressing the individual symptoms of each patient. This may involve a combination of medications, physical therapy and supplements.

MalaCards based summary : Childhood Type Dermatomyositis, also known as juvenile dermatomyositis, is related to interstitial lung disease and enthesopathy. An important gene associated with Childhood Type Dermatomyositis is CCR6 (C-C Motif Chemokine Receptor 6), and among its related pathways/superpathways are Allograft rejection and NF-kappaB Signaling. The drugs Abatacept and Vaccines have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, skin and heart, and related phenotypes are muscle weakness and fatigue

Wikipedia : 74 Juvenile dermatomyositis (JDM) is an idiopathic inflammatory myopathy (IMM) of presumed autoimmune... more...

Sources

Related Diseases for Childhood Type Dermatomyositis

About this section

Diseases related to Childhood Type Dermatomyositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 466)
# Related Disease Score Top Affiliating Genes
1 interstitial lung disease 31.3 TRIM21 TNF MORC3 IFIH1
2 enthesopathy 30.9 TNFRSF1B TNF CCR6
3 pustulosis of palm and sole 30.7 TNFRSF1B TNF CCR6
4 skin disease 30.5 TNFRSF1B TNF MX1 ICOSLG CD4 CCR6
5 autoimmune vasculitis 30.5 TNF CD4 CCR6
6 macrophage activation syndrome 30.4 TNFRSF1B TNF
7 t cell deficiency 30.3 ICOSLG CD4 CCR6
8 lupus erythematosus 30.2 TRIM21 TNFRSF1B TNF SNRNP70 MX1
9 pericarditis 30.2 TNF PIK3C2A CD4
10 respiratory failure 30.2 TNF PIK3C2A CD4 CCR6
11 autoimmune gastritis 30.1 TNF ICOSLG CD4 CCR6
12 cellulitis 30.1 TNF ICOSLG CD4 CCR6
13 celiac disease 1 30.0 TNF IFNA1 ICOSLG CD4 CCR6
14 pneumonia 30.0 TNFRSF1B TNF PIK3C2A IFNA1
15 muscular disease 30.0 TNF PIK3C2A MIR10A IFIH1 ICOSLG CCR6
16 central nervous system disease 30.0 TNF MIR10A ICOSLG CCR6
17 psoriasis 29.9 TNFRSF1B TNF MIR10A IFIH1 CD4 CCR6
18 nervous system disease 29.9 TNF MIR10A ICOSLG CD4 CCR6
19 mumps 29.8 TNFRSF1B TNF MX1 IFNA1
20 influenza 29.8 TNF MX1 MORC3 IFNA1 IFIH1
21 bacterial infectious disease 29.8 TNF MX1 ICOSLG CD4 CCR6
22 chickenpox 29.7 TNFRSF1B TNF IFNA1 CD4 CCR6
23 immune deficiency disease 29.7 TNF IFNA1 ICOSLG CD4 CCR6
24 autoimmune disease 29.6 TRIM21 TNFRSF1B TNF IFNA1 ICOSLG CCR6
25 herpes zoster 29.5 TNFRSF1B TNF IFNA1 ICOSLG CD4 CCR6
26 adult dermatomyositis 29.3 TRIM33 TRIM24 TNF MORC3 IFNA1 IFIH1
27 systemic scleroderma 29.3 TRIM21 TNF SNRNP70 ICOSLG EXOSC10 CD4
28 connective tissue disease 29.2 TNFRSF1B TNF SNRNP70 MIR10A ICOSLG CD4
29 systemic lupus erythematosus 29.0 TRIM21 TNFRSF1B TNF SNRNP70 MX1 IFNA1
30 myositis 28.8 TRIM33 TRIM21 TNF PIK3C2A NT5C1A IFNA1
31 exanthem 28.6 TRIM21 TNFRSF1B TNF PIK3C2A IFNA1 IFIH1
32 dermatomyositis 10.6
33 juvenile overlap myositis 10.5
34 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 10.5
35 lung disease 10.5
36 subacute cutaneous lupus erythematosus 10.5 TRIM21 TNF
37 mulchandani-bhoj-conlin syndrome 10.5 ICOSLG CXCR5 CCR6
38 hypersensitivity reaction type iii disease 10.5 TNF ICOSLG CCR6
39 posterior uveitis 10.4 TNF ICOSLG CCR6
40 dacryoadenitis 10.4 ICOSLG CD4 CCR6
41 myelitis 10.4 TNF ICOSLG CCR6
42 monoclonal gammopathy of uncertain significance 10.4 TNF ICOSLG CCR6
43 chronic orbital inflammation 10.4 TNFRSF1B MORC3
44 facial hemiatrophy 10.4 SNRNP70 EXOSC10
45 legume allergy 10.4 ICOSLG CD4 CCR6
46 fruit allergy 10.4 ICOSLG CD4 CCR6
47 autoimmune glomerulonephritis 10.4 ICOSLG CD4 CCR6
48 autoimmune disease of urogenital tract 10.4 ICOSLG CD4 CCR6
49 intestinal schistosomiasis 10.4 ICOSLG CD4 CCR6
50 juvenile ankylosing spondylitis 10.4 TNFRSF1B TNF

Graphical network of the top 20 diseases related to Childhood Type Dermatomyositis:



Diseases related to Childhood Type Dermatomyositis
Sources

Symptoms & Phenotypes for Childhood Type Dermatomyositis

About this section

Human phenotypes related to Childhood Type Dermatomyositis:

58 31 (show all 45)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 muscle weakness 58 31 hallmark (90%) Very frequent (99-80%) HP:0001324
2 fatigue 58 31 hallmark (90%) Very frequent (99-80%) HP:0012378
3 elevated serum creatine kinase 58 31 hallmark (90%) Very frequent (99-80%) HP:0003236
4 dry skin 58 31 hallmark (90%) Very frequent (99-80%) HP:0000958
5 skin rash 58 31 hallmark (90%) Very frequent (99-80%) HP:0000988
6 erythema 58 31 hallmark (90%) Very frequent (99-80%) HP:0010783
7 telangiectasia of the skin 58 31 hallmark (90%) Very frequent (99-80%) HP:0100585
8 autoimmunity 58 31 hallmark (90%) Very frequent (99-80%) HP:0002960
9 myalgia 58 31 hallmark (90%) Very frequent (99-80%) HP:0003326
10 mucosal telangiectasiae 58 31 hallmark (90%) Very frequent (99-80%) HP:0100579
11 myositis 58 31 hallmark (90%) Very frequent (99-80%) HP:0100614
12 palpebral edema 58 31 hallmark (90%) Very frequent (99-80%) HP:0100540
13 elevated c-reactive protein level 58 31 hallmark (90%) Very frequent (99-80%) HP:0011227
14 elevated erythrocyte sedimentation rate 58 31 hallmark (90%) Very frequent (99-80%) HP:0003565
15 calcinosis 58 31 hallmark (90%) Very frequent (99-80%) HP:0003761
16 muscular hypotonia 58 31 frequent (33%) Frequent (79-30%) HP:0001252
17 arthritis 58 31 frequent (33%) Frequent (79-30%) HP:0001369
18 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
19 pruritus 58 31 frequent (33%) Frequent (79-30%) HP:0000989
20 cutaneous photosensitivity 58 31 frequent (33%) Frequent (79-30%) HP:0000992
21 arthralgia 58 31 frequent (33%) Frequent (79-30%) HP:0002829
22 skin ulcer 58 31 frequent (33%) Frequent (79-30%) HP:0200042
23 restrictive ventilatory defect 58 31 frequent (33%) Frequent (79-30%) HP:0002091
24 alopecia 58 31 frequent (33%) Frequent (79-30%) HP:0001596
25 constipation 58 31 frequent (33%) Frequent (79-30%) HP:0002019
26 vasculitis 58 31 frequent (33%) Frequent (79-30%) HP:0002633
27 muscle spasm 58 31 frequent (33%) Frequent (79-30%) HP:0003394
28 poikiloderma 58 31 frequent (33%) Frequent (79-30%) HP:0001029
29 dysphagia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002015
30 dyspnea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002094
31 emg abnormality 58 31 occasional (7.5%) Occasional (29-5%) HP:0003457
32 arrhythmia 58 31 occasional (7.5%) Occasional (29-5%) HP:0011675
33 weight loss 58 31 occasional (7.5%) Occasional (29-5%) HP:0001824
34 pericarditis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001701
35 abdominal pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002027
36 pulmonary fibrosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002206
37 gastrointestinal hemorrhage 58 31 occasional (7.5%) Occasional (29-5%) HP:0002239
38 cough 58 31 occasional (7.5%) Occasional (29-5%) HP:0012735
39 angina pectoris 58 31 occasional (7.5%) Occasional (29-5%) HP:0001681
40 bundle branch block 58 31 occasional (7.5%) Occasional (29-5%) HP:0011710
41 dysarthria 58 31 occasional (7.5%) Occasional (29-5%) HP:0001260
42 hoarse voice 58 31 occasional (7.5%) Occasional (29-5%) HP:0001609
43 dysphonia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001618
44 limitation of joint mobility 58 31 occasional (7.5%) Occasional (29-5%) HP:0001376
45 cardiomyopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0001638
Sources

Drugs & Therapeutics for Childhood Type Dermatomyositis

About this section

Drugs for Childhood Type Dermatomyositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 56)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Abatacept Approved Phase 4 332348-12-6 10237
2 Vaccines Phase 4
3 Adrenocorticotropic Hormone Phase 4
4 Melanocyte-Stimulating Hormones Phase 4
5 beta-Endorphin Phase 4
6 Immunologic Factors Phase 4
7 Immunosuppressive Agents Phase 4
8 Antirheumatic Agents Phase 4
9
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
10
Alendronate Approved Phase 2, Phase 3 66376-36-1, 121268-17-5 2088
11
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
12
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
13
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
14 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
15
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
16
Methotrexate Approved Phase 2, Phase 3 59-05-2, 1959-05-2 126941
17
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
18
Prednisone Approved, Vet_approved Phase 2, Phase 3 53-03-2 5865
19
Etanercept Approved, Investigational Phase 2, Phase 3 185243-69-0
20
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
21
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
22 Cyclosporins Phase 3
23 Methylprednisolone Acetate Phase 3
24 glucocorticoids Phase 2, Phase 3
25 Folate Phase 2, Phase 3
26 Vitamin B9 Phase 2, Phase 3
27 Hormone Antagonists Phase 2, Phase 3
28 Hormones Phase 2, Phase 3
29 Vitamin B Complex Phase 2, Phase 3
30 Folic Acid Antagonists Phase 2, Phase 3
31 Antineoplastic Agents, Hormonal Phase 2, Phase 3
32 Dermatologic Agents Phase 2, Phase 3
33 Antimetabolites Phase 2, Phase 3
34 Anti-Inflammatory Agents Phase 2, Phase 3
35 Gastrointestinal Agents Phase 2, Phase 3
36 Analgesics, Non-Narcotic Phase 2, Phase 3
37 Analgesics Phase 2, Phase 3
38 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
39
rituximab Approved Phase 2 174722-31-7 10201696
40 Antiemetics Phase 2
41 Neuroprotective Agents Phase 2
42 Pharmaceutical Solutions Phase 2
43 Antineoplastic Agents, Immunological Phase 2
44 Protective Agents Phase 2
45 Antidotes Phase 2
46 Antioxidants Phase 2
47 Chelating Agents Phase 2
48 Antitubercular Agents Phase 2
49 Anti-Infective Agents Phase 2
50 Anti-Bacterial Agents Phase 2

Interventional clinical trials:

(show all 28)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
2 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
3 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Recruiting NCT02245841 Phase 4 H.P. Acthar Gel
4 Abatacept for the Treatment of Refractory Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
5 Five-year Single-blind, Phase III Effectiveness Randomised Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis: Prednisone Versus Prednisone Plus Cyclosporine a Versus Prednisone Plus Methotrexate Unknown status NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
6 Double Blind Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid-Associated Osteopenia and Osteoporosis Unknown status NCT00209469 Phase 2, Phase 3 alendronate sodium
7 Double-Blinded Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid- Associated Osteopenia and Osteoporosis Completed NCT00277251 Phase 2, Phase 3 Alendronate
8 A Prospective, Randomised, Assessor-blind, Multicenter Study of Efficacy and Safety of Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With Polymyositis and Dermatomyositis. Completed NCT00651040 Phase 3 Prednisone;Methotrexate
9 Toward Improved Understanding of Pathogenesis and Treatment of Childhood Onset Dermatomyositis Terminated NCT00035958 Phase 2, Phase 3 Prednisone;Methotrexate;Etanercept
10 Phase II Study of Prednisolone/Methylprednisolone Absorption in Children With Juvenile Dermatomyositis Completed NCT00004357 Phase 2 Methylprednisolone;Prednisolone
11 Novel Drug Delivery of Sodium Thiosulfate for Calcinosis Associated With Adult and Juvenile Dermatomyositis Completed NCT01572844 Phase 2 Sodium thiosulfate
12 Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Completed NCT02043548 Phase 2 tocilizumab;placebo
13 Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathy (IIM) Completed NCT00106184 Phase 2 Rituximab;Placebo
14 An Open-label Study of Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Recruiting NCT03267277 Phase 2 Sodium Thiosulfate
15 Incidence and Prevalence of Juvenile Dermatomyositis in Alsace Between 2000 to 2015 Unknown status NCT03432455
16 Retrospective Descriptive Study of Juvenile Dermatomyositis in Alsace Unknown status NCT03433638
17 Efficacy and Safety of Creatine Supplementation in Patients With Juvenile Systemic Lupus Erythematosus and Juvenile Dermatomyositis Unknown status NCT01217320
18 Studies on Tissues From Patients With Fibrous Dysplasia of Bone/McCune-Albright Syndrome and Other Disorders of Calcified Tissues Completed NCT00001973
19 The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis Completed NCT02267005
20 Fatigue and Sleep in Children and Adolescents With Juvenile Idiopathic Arthritis: A Cross-Sectional Study Completed NCT03618680
21 Evaluation of Yellow Fever Vaccine in Patients With Rheumatic Diseases Under Low Immunosuppression Level and Residing in a Risk Area Completed NCT03430388
22 The CARRA Registry Completed NCT01697254
23 Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study (STOPP-CIS) Completed NCT01663129
24 Studies of Natural History, Pathogenesis, and Outcomes in Autoimmune and Inflammatory Diseases Including Juvenile Dermatomyositis Recruiting NCT00059748
25 Pathogenic Studies In Families With Twins Or Siblings Discordant For Systemic Rheumatic Disorders Recruiting NCT00055055
26 MYOPROSP: A Prospective Cohort Study to Identify a Stratified Approach in the Diagnosis, Treatment and Delivery of Care in Adult Idiopathic Inflammatory Myopathy Recruiting NCT02468895
27 Arthritis in Assiut University Children Hospital Not yet recruiting NCT04326582
28 Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI and Severe Juvenile Dermatomyositis No longer available NCT01724580 Baricitinib

Search NIH Clinical Center for Childhood Type Dermatomyositis

Sources

Genetic Tests for Childhood Type Dermatomyositis

About this section
Sources

Anatomical Context for Childhood Type Dermatomyositis

About this section

MalaCards organs/tissues related to Childhood Type Dermatomyositis:

40
Skeletal Muscle, Skin, Heart, Bone, Lung, T Cells, Testes
Sources

Publications for Childhood Type Dermatomyositis

About this section

Articles related to Childhood Type Dermatomyositis:

(show top 50) (show all 1111)
# Title Authors PMID Year
1
Type I Interferons in the Pathogenesis and Treatment of Autoimmune Diseases. 61
32557263 2020
2
Juvenile Dermatomyositis and the Inflammatory Myopathies. 61
32252099 2020
3
Calcinosis Biomarkers in Adult and Juvenile Dermatomyositis. 61
32234404 2020
4
[Juvenile dermatomyositis: A series of 22 cases]. 61
32532518 2020
5
Efficacy of Repository-Corticotropin Injection (Acthar) in Refractory Juvenile Dermatomyositis: A Case Series. 61
32501940 2020
6
Epidemiology of juvenile dermatomyositis in Alsace. 61
31823358 2020
7
Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-Update. 61
31955618 2020
8
Macrophage activation syndrome in juvenile dermatomyositis: a systematic review. 61
31529231 2020
9
Juvenile dermatomyositis presenting as complete heart block in a 10-year-old girl. 61
32427522 2020
10
Functional and Structural Adaptations of Skeletal Muscle in Long-Term Juvenile Dermatomyositis: A Controlled Cross-Sectional Study. 61
31746550 2020
11
Inhibition of IFNα secretion in cells from patients with juvenile dermatomyositis under TBK1 inhibitor treatment revealed by single-molecular assay technology. 61
31971592 2020
12
Inhibition of IFNα secretion in cells from patients with juvenile dermatomyositis under TBK1 inhibitor treatment revealed by single-molecular assay technology. 61
31665500 2020
13
Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. 61
31874111 2020
14
Spectrum of paediatric rheumatic disorders at a tertiary hospital in Tanzania. 61
32245494 2020
15
Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients. 61
32293539 2020
16
Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies. 61
32252809 2020
17
Periorbital Edema as the Initial Sign of Juvenile Dermatomyositis. 61
30234551 2020
18
[A case of juvenile dermatomyositis with neuromyelitis optica spectrum disorders]. 61
32234143 2020
19
Diffuse Lacy Reticular Calcinosis in Juvenile Dermatomyositis. 61
32251056 2020
20
Subcutaneous granuloma annulare mimicking dermatomyositis. 61
32314413 2020
21
Self-healing juvenile cutaneous mucinosis, a sclerodermoid disorder simulating juvenile dermatomyositis: a case-based review. 61
32462254 2020
22
Pilot study of the juvenile dermatomyositis consensus treatment plans: a CARRA Registry study. 61
32238513 2020
23
Juvenile Dermatomyositis and Development of Malignancy: 2 Case Reports and a Literature Review. 61
31941800 2020
24
Relapsing retroperitoenal abscess secondary to juvenile dermatomyositis: Complexity in management. 61
32281605 2020
25
Assessment of traditional and non-traditional risk factors for premature atherosclerosis in children with juvenile dermatomyositis and pediatric controls. 61
32183829 2020
26
Transitional B cells involved in autoimmunity and their impact on neuroimmunological diseases. 61
32183811 2020
27
Long-term outcome in children with juvenile dermatomyositis: A single-center study from north India. 61
31793219 2020
28
The spectrum of idiopathic inflammatory myopathies in South Africa. 61
32212001 2020
29
Correlation of a Modified Disease Activity Score with the Validated Original Disease Activity Score in Patients with Juvenile Dermatomyositis. 61
32173660 2020
30
Image Gallery: Antihelix red-violaceous macules in juvenile dermatomyositis associated with antimelanoma differentiation-associated protein 5 antibody. 61
31598963 2020
31
Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment. 61
31556011 2020
32
Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis. 61
31707357 2020
33
Endothelial and Inflammation Biomarker Profiles at Diagnosis Reflecting Clinical Heterogeneity and Serving as a Prognostic Tool For Treatment Response in Two Independent Cohorts of Patients With Juvenile Dermatomyositis. 61
32103637 2020
34
Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: A review of the literature. 61
31302187 2020
35
Neutrophil Extracellular Traps in Tissue and Periphery in Juvenile Dermatomyositis. 61
31403247 2020
36
Growth and Puberty in Juvenile Dermatomyositis: A Longitudinal Cohort Study. 61
31507092 2020
37
Severe Abdominal Manifestations in Juvenile Dermatomyositis. 61
31978027 2020
38
Visual Dermatology: Gottron Papules in a Child: Juvenile Dermatomyositis. 61
31994926 2020
39
Case Report of a Rare Case of Juvenile Dermatomyositis Sine Dermatitis. 61
31979712 2020
40
Hypopigmentation in the Medial Angle of Eyes in a Young Boy With Juvenile Dermatomyositis. 61
31977652 2020
41
Symmetrical cutaneous ulcers: Are they associated with severe disease in children with juvenile dermatomyositis? 61
31449488 2020
42
Abatacept in the Treatment of Juvenile Dermatomyositis-Associated Calcifications in a 16-Year-Old Girl. 61
32550037 2020
43
Vaccination coverage in children with rheumatic diseases. 61
31577215 2020
44
Juvenile dermatomyositis resembling late-stage Degos disease with gastrointestinal perforations successfully treated with combination of cyclophosphamide and rituximab: case-based review. 61
31900501 2020
45
Scrotal and Penile Ulcer in Juvenile Dermatomyositis: An Unusual Occurrence. 61
29561468 2020
46
Patient and physician discordance of global disease assessment in juvenile dermatomyositis: findings from the Childhood Arthritis & Rheumatology Research Alliance Legacy Registry. 61
31941511 2020
47
Pamidronate in Treatment of Calcinosis in Juvenile Dermatomyositis. 61
31937708 2020
48
Using peripheral blood immune signatures to stratify patients with adult and juvenile inflammatory myopathies. 61
31292651 2020
49
Co-expression network analysis reveals the pivotal role of mitochondrial dysfunction and interferon signature in juvenile dermatomyositis. 61
32110496 2020
50
Erratum corrige: "Treatment of calcinosis with adult and juvenile dermatomyositis using topical sodium thiosulfate via fractionated CO2 laser treatment".M.G. Eleryan et al. 61
32041681 2020
Sources

Variations for Childhood Type Dermatomyositis

About this section
Sources

Expression for Childhood Type Dermatomyositis

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Childhood Type Dermatomyositis patients vs. healthy controls: 35 (show all 35)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 IFIT3 interferon-induced protein with tetratricopeptide repeats 3 Skeletal Muscle + 5.58 0.000
2 ISG15 ISG15 ubiquitin-like modifier Skeletal Muscle + 5.25 0.000
3 XIST X inactive specific transcript (non-protein coding) Skeletal Muscle + 5.14 0.000
4 RSAD2 radical S-adenosyl methionine domain containing 2 Skeletal Muscle + 4.94 0.000
5 GBP1 guanylate binding protein 1, interferon-inducible Skeletal Muscle + 4.88 0.000
6 CMPK2 cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial Skeletal Muscle + 4.61 0.000
7 IFI44L interferon-induced protein 44-like Skeletal Muscle + 4.42 0.000
8 MX1 MX dynamin-like GTPase 1 Skeletal Muscle + 4.40 0.000
9 IFI44 interferon-induced protein 44 Skeletal Muscle + 4.34 0.000
10 IFIT2 interferon-induced protein with tetratricopeptide repeats 2 Skeletal Muscle + 3.96 0.000
11 IFI27 interferon, alpha-inducible protein 27 Skeletal Muscle + 3.86 0.000
12 CXCL11 chemokine (C-X-C motif) ligand 11 Skeletal Muscle + 3.67 0.000
13 RPS4Y1 ribosomal protein S4, Y-linked 1 Skeletal Muscle - 3.57 0.000
14 IFIT1 interferon-induced protein with tetratricopeptide repeats 1 Skeletal Muscle + 3.57 0.000
15 MYH3 myosin, heavy chain 3, skeletal muscle, embryonic Skeletal Muscle + 3.54 0.000
16 SAMHD1 SAM domain and HD domain 1 Skeletal Muscle + 3.52 0.000
17 XAF1 XIAP associated factor 1 Skeletal Muscle + 3.44 0.000
18 KLHDC7B kelch domain containing 7B Skeletal Muscle + 3.44 0.000
19 IFI6 interferon, alpha-inducible protein 6 Skeletal Muscle + 3.43 0.000
20 IFIH1 interferon induced with helicase C domain 1 Skeletal Muscle + 3.43 0.000
21 PARP12 poly (ADP-ribose) polymerase family, member 12 Skeletal Muscle + 3.41 0.000
22 IFI16 interferon, gamma-inducible protein 16 Skeletal Muscle + 3.40 0.000
23 PLSCR1 phospholipid scramblase 1 Skeletal Muscle + 3.37 0.000
24 STAT1 signal transducer and activator of transcription 1, 91kDa Skeletal Muscle + 3.37 0.000
25 PSMB8 proteasome subunit beta 8 Skeletal Muscle + 3.35 0.000
26 NNMT nicotinamide N-methyltransferase Skeletal Muscle + 3.31 0.000
27 TRIM22 tripartite motif containing 22 Skeletal Muscle + 3.27 0.000
28 DTX3L deltex 3 like, E3 ubiquitin ligase Skeletal Muscle + 3.23 0.000
29 EIF2AK2 eukaryotic translation initiation factor 2-alpha kinase 2 Skeletal Muscle + 3.14 0.000
30 IRF7 interferon regulatory factor 7 Skeletal Muscle + 3.13 0.000
31 OAS1 2'-5'-oligoadenylate synthetase 1, 40/46kDa Skeletal Muscle + 3.09 0.000
32 IFITM1 interferon induced transmembrane protein 1 Skeletal Muscle + 3.06 0.000
33 TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 Skeletal Muscle + 3.05 0.000
34 PARP9 poly (ADP-ribose) polymerase family, member 9 Skeletal Muscle + 3.05 0.000
35 POSTN periostin, osteoblast specific factor Skeletal Muscle + 3.03 0.000
Search GEO for disease gene expression data for Childhood Type Dermatomyositis.
Sources

Pathways for Childhood Type Dermatomyositis

About this section

Pathways related to Childhood Type Dermatomyositis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Allograft rejection 1 36
Show member pathways
 12.4 TNF IFNA1 ICOSLG CXCR5 CD4
2
NF-kappaB Signaling 4
11.87 TNFRSF1B TNF IFNA1 IFIH1 CXCR5
3
Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 11.79 TNFRSF1B TNF CXCR5 CCR6
4
Innate Lymphoid Cells Differentiation 64
10.83 TNF CXCR5 CD4 CCR6
Sources

GO Terms for Childhood Type Dermatomyositis

About this section

Cellular components related to Childhood Type Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.02 TNF ICOSLG CXCR5 CD4 CCR6

Biological processes related to Childhood Type Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.65 TNFRSF1B TNF CXCR5 CD4 CCR6
2 positive regulation of viral entry into host cell GO:0046598 9.16 TRIM21 CD4
3 humoral immune response GO:0006959 9.13 TNF IFNA1 CCR6
4 defense response GO:0006952 8.92 TNF MX1 IFNA1 ICOSLG

Molecular functions related to Childhood Type Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.43 TRIM33 TRIM24 TRIM21 MORC3 IFIH1 CD4
2 identical protein binding GO:0042802 9.23 TRIM21 TNF MX1 IFIH1 ICOSLG DMBX1
Sources

Sources for Childhood Type Dermatomyositis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....